Actavis PLC (ACT): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Actavis fell $4.40 (-2.1%) to $208.78 on average volume. Throughout the day, 3,059,998 shares of Actavis exchanged hands as compared to its average daily volume of 2,155,200 shares. The stock ranged in price between $206.49-$212.74 after having opened the day at $209.56 as compared to the previous trading day's close of $213.18. Other companies within the Drugs industry that declined today were: Biostar Pharmaceuticals ( BSPM), down 19.2%, Reliv' International ( RELV), down 11.6%, Pacific Biosciences of California ( PACB), down 7.0% and Enzymotec ( ENZY), down 5.9%.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $37.3 billion and is part of the health care sector. Shares are up 27.4% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.

On the positive front, Northwest Biotherapeutics ( NWBO), up 29.6%, Egalet ( EGLT), up 25.6%, Rosetta Genomics ( ROSG), up 16.4% and Aastrom Biosciences ( ASTM), up 16.1% , were all gainers within the drugs industry with Intercept Pharmaceuticals ( ICPT) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Skechers Slumps the Most in Two Years After Soft Guidance Overshadows Solid Q1

Skechers Slumps the Most in Two Years After Soft Guidance Overshadows Solid Q1

Video: This Is One Way Millennials Are Destroying Their Financial Future

Video: This Is One Way Millennials Are Destroying Their Financial Future

What Do Trade Wars Mean for High Yield Bond Investors?

What Do Trade Wars Mean for High Yield Bond Investors?

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite